Literature DB >> 27563394

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Clemens Scheufler1, Henrik Möbitz1, Christoph Gaul1, Christian Ragot1, Céline Be1, César Fernández1, Kim S Beyer1, Ralph Tiedt1, Frédéric Stauffer1.   

Abstract

Mixed lineage leukemia (MLL) gene rearrangement induces leukemic transformation by ectopic recruitment of disruptor of telomeric silencing 1-like protein (DOT1L), a lysine histone methyltransferase, leading to local hypermethylation of H3K79 and misexpression of genes (including HoxA), which drive the leukemic phenotype. A weak fragment-based screening hit identified by SPR was cocrystallized with DOT1L and optimized using structure-based ligand optimization to yield compound 8 (IC50 = 14 nM). This series of inhibitors is structurally not related to cofactor SAM and is not interacting within the SAM binding pocket but induces a pocket adjacent to the SAM binding site.

Entities:  

Keywords:  Dot1L; fragment-based screen; inhibitor; lysine histone methyltransferase; structure-based design

Year:  2016        PMID: 27563394      PMCID: PMC4983739          DOI: 10.1021/acsmedchemlett.6b00168

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

1.  Structural basis for signal-sequence recognition by the translocase motor SecA as determined by NMR.

Authors:  Ioannis Gelis; Alexandre M J J Bonvin; Dimitra Keramisanou; Marina Koukaki; Giorgos Gouridis; Spyridoula Karamanou; Anastassios Economou; Charalampos G Kalodimos
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

Review 2.  Ligand efficiency and fragment-based drug discovery.

Authors:  Scott D Bembenek; Brett A Tounge; Charles H Reynolds
Journal:  Drug Discov Today       Date:  2008-12-30       Impact factor: 7.851

3.  Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Authors:  Wenyu Yu; David Smil; Fengling Li; Wolfram Tempel; Oleg Fedorov; Kong T Nguyen; Yuri Bolshan; Rima Al-Awar; Stefan Knapp; Cheryl H Arrowsmith; Masoud Vedadi; Peter J Brown; Matthieu Schapira
Journal:  Bioorg Med Chem       Date:  2013-01-30       Impact factor: 3.641

Review 4.  The diverse functions of Dot1 and H3K79 methylation.

Authors:  Anh Tram Nguyen; Yi Zhang
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

5.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

6.  Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase.

Authors:  Jinrong Min; Qin Feng; Zhizhong Li; Yi Zhang; Rui-Ming Xu
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

Review 7.  Oncoepigenomics: making histone lysine methylation count.

Authors:  Daniel Decarlo; M Kyle Hadden
Journal:  Eur J Med Chem       Date:  2012-08-11       Impact factor: 6.514

8.  Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.

Authors:  Lisheng Deng; Li Zhang; Yuan Yao; Cong Wang; Michele S Redell; Shuo Dong; Yongcheng Song
Journal:  Medchemcomm       Date:  2013-05-01       Impact factor: 3.597

9.  hDOT1L links histone methylation to leukemogenesis.

Authors:  Yuki Okada; Qin Feng; Yihui Lin; Qi Jiang; Yaqiang Li; Vernon M Coffield; Lishan Su; Guoliang Xu; Yi Zhang
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

10.  Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.

Authors:  Justin L Anglin; Lisheng Deng; Yuan Yao; Guobin Cai; Zhen Liu; Hong Jiang; Gang Cheng; Pinhong Chen; Shuo Dong; Yongcheng Song
Journal:  J Med Chem       Date:  2012-09-06       Impact factor: 7.446

View more
  18 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

2.  Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Authors:  Henrik Möbitz; Rainer Machauer; Philipp Holzer; Andrea Vaupel; Frédéric Stauffer; Christian Ragot; Giorgio Caravatti; Clemens Scheufler; Cesar Fernandez; Ulrich Hommel; Ralph Tiedt; Kim S Beyer; Chao Chen; Hugh Zhu; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2017-02-14       Impact factor: 4.345

Review 3.  Recent progress in developing selective inhibitors of protein methyltransferases.

Authors:  H Ümit Kaniskan; Jian Jin
Journal:  Curr Opin Chem Biol       Date:  2017-06-26       Impact factor: 8.822

4.  New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Authors:  Frédéric Stauffer; Andreas Weiss; Clemens Scheufler; Henrik Möbitz; Christian Ragot; Kim S Beyer; Keith Calkins; Daniel Guthy; Michael Kiffe; Bernard Van Eerdenbrugh; Ralph Tiedt; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2019-12-04       Impact factor: 4.345

5.  Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L.

Authors:  Evan J Worden; Niklas A Hoffmann; Chad W Hicks; Cynthia Wolberger
Journal:  Cell       Date:  2019-02-11       Impact factor: 41.582

6.  Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Authors:  Chao Chen; Hugh Zhu; Frédéric Stauffer; Giorgio Caravatti; Susanne Vollmer; Rainer Machauer; Philipp Holzer; Henrik Möbitz; Clemens Scheufler; Martin Klumpp; Ralph Tiedt; Kim S Beyer; Keith Calkins; Daniel Guthy; Michael Kiffe; Jeff Zhang; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2016-06-01       Impact factor: 4.345

Review 7.  Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.

Authors:  Nigel J Waters
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

Review 8.  Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Authors:  Kamakoti P Bhat; H Ümit Kaniskan; Jian Jin; Or Gozani
Journal:  Nat Rev Drug Discov       Date:  2021-01-19       Impact factor: 84.694

9.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

10.  Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

Authors:  Garrett S Gibbons; Amarraj Chakraborty; Sierrah M Grigsby; Afoma C Umeano; Chenzhong Liao; Omar Moukha-Chafiq; Vibha Pathak; Bini Mathew; Young-Tae Lee; Yali Dou; Stephan C Schürer; Robert C Reynolds; Timothy S Snowden; Zaneta Nikolovska-Coleska
Journal:  Eur J Med Chem       Date:  2020-01-02       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.